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Verona, Mantova, Vicenza, Agrigento, Roma, Catania, Catanzaro, Milano, Genova, Torino, Bologna,
and Vigevano, ItalyObjectives This study sought to investigate the efﬁcacy and performance of the XIENCE V everolimus-
eluting stent (EES) (Abbott Vascular, Santa Clara, California) in the treatment of de novo coronary
lesions in patients with 2- to 3-vessel multivessel coronary artery disease (MV-CAD).
Background Drug-eluting stents (DES) have emerged as an alternative to conventional coronary
artery bypass surgery in patients with MV-CAD although ﬁrst-generation DES yielded inferior efﬁcacy
and safety compared with surgery.
Methods Prospective, randomized (1:1), multicenter feasibility trial was designed to assess
angiographic efﬁcacy of EES compared with the TAXUS paclitaxel-eluting stent (PES) in 200 patients,
and a prospective, open-label, single-arm, controlled registry was designed to analyze the clinical
outcome of EES at 1-year follow-up in 400 MV-CAD patients. For the randomized trial, the primary
endpoint was in-stent late loss at 9 months. For the registry, the primary endpoint was a composite of
all-cause death, myocardial infarction, and ischemia-driven target vessel revascularization at 12 months.
Results The primary endpoint per single lesion was signiﬁcantly lower in the EES group compared
with the PES group (0.03  0.49 mm vs. 0.23  0.51 mm, p ¼ 0.001). Similar results were observed
when analyzing all lesions (0.05  0.51 mm vs. 0.24  0.50 mm, p < 0.001). Clinical outcome at 1 year
yielded a composite of major adverse cardiac events of 9.2% in the single-arm registry, and 11.1% and
16.5% in the EES and PES randomized groups, respectively (p ¼ 0.30).
Conclusions The EXECUTIVE trial was a randomized pilot trial dedicated to the comparison of the
efﬁcacy of 2 different DES among patients with 2- to 3-vessel MV-CAD. The study shows lower in-stent
late loss at 9 months with the EES XIENCE V compared with the PES TAXUS Libertè, and a low major
adverse cardiac event rate at 1 year in patients with 2-to 3-vessel MV-CAD. (EXECUTIVE [EXecutive RCT:
Evaluating XIENCE V in a Multi Vessel Disease]; NCT00531011) (J Am Coll Cardiol Intv 2013;6:1012–22)
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1013Progress in medical care and economic and social develop-
ment result in a continuous increment of life expectancy,
and elderly patients are frequently exposed to widespread
forms of atherosclerosis. In most cases, patients with mul-
tivessel (MV) coronary artery disease (CAD) have diffuse
atherosclerosis and complex lesions, are often diabetic,
and present with impaired left ventricular function. Initial
comparisons between percutaneous coronary interventionSee page 1023
Abbreviations
and Acronyms
CAD = coronary artery
disease
CI = conﬁdence interval
DES = drug-eluting stent(s)
EES = everolimus-eluting
stent(s)
MACE = major adverse
cardiac event(s)
MLD = minimal lumen
diameter
MV = multivessel
PCI = percutaneous coronary
intervention
PES = paclitaxel-eluting
stent(s)
QCA = quantitative coronary
angiography
TVR = target vessel
revascularization(PCI) with bare-metal stents and coronary artery bypass
graft surgery had shown a relative equivalence of the 2 treat-
ments in terms of survival, but a clearly higher efﬁcacy
of surgery in preventing ischemic recurrences (1–4). Such
studies, however, included patients with relatively low an-
giographic complexity and with 1- or 2-vessel disease in over
40% of cases, and excluded patients with left main lesions
or impaired left ventricular function, a selection that clearly
reduced the potential beneﬁts of surgery (5). With the
advent of drug-eluting stents (DES), results of PCI
improved signiﬁcantly (6,7), but unlike surgery, remained
strongly inﬂuenced by the severity and extent of the MV-
CAD. Such differences was clearly demonstrated in
the SYNTAX (Synergy Between Percutaneous Coronary
Intervention With Taxus and Cardiac Surgery) trial, a real
“all-comers study” that randomized patients with 3-vessel
disease, including those with left main stenosis, to PCI
with DES or to coronary surgery (8,9). Based on such
observations, recent guidelines on myocardial revascular-
ization conﬁrm the superiority of coronary bypass surgery over
PCI in patients with MV-CAD, in particular in those cases
with diffuse disease as expressed by intermediate or high
SYNTAX scores, whereas PCI is considered to be an
appropriate alternative in patients with limited angiographic
complexity (10–12). The recently developed SYNTAX score
II (13) has demonstrated the ability to better guide decision
making between surgery and PCI than the assessment
provided by the anatomic SYNTAX score alone. Current
recommendations, however, are based on the results obtained
with sirolimus-eluting stents and paclitaxel-eluting stents
(PES), both considered to belong to the “ﬁrst generation” of
DES.From the *Department of Medicine, Università di Verona, Verona, Italy; yAzienda
Ospedaliera Carlo Poma, Mantova, Italy; zOspedale san Bortolo, Vicenza, Italy;
xAzienda Ospedaliera San Giovanni di Dio, Agrigento, Italy; kOspedale Sandro
Pertini, Roma, Italy; {Ospedale Generale Madre Vannini, Roma, Italy; #Azienda
Ospedaliera Cannizzaro, Catania, Italy; **Azienda Ospedaliera Mater Domini
Università degli Studi Magna Graecia, Catanzaro, Italy; yyIRCCS Centro Car-
diologico Monzino, Milano, Italy; zzEnte Ospedaliero Ospedali Galliera, Genova,
Italy; xxOspedale Maria Vittoria, Torino, Italy; kkOspedale Maggiore, Bologna,
Italy; {{Azienda Ospedaliera di Pavia e provincia, Ospedale di Vigevano, Vigevano,
Italy; ##Azienda Ospedaliera S. Andrea, Roma, Italy; ***Azienda OspedalieraMore recent investigations have demonstrated signiﬁ-
cantly better clinical and angiographic outcomes of a new-
generation everolimus-eluting stent (EES) compared with
PES (14–16). The availability of safer and more effective
DES generates the hypothesis that these may reduce the gap
between PCI and surgery in patients with MV-CAD.
However, despite the myriad of studies performed with
DES, patients with advanced MV-CAD have been regularly
excluded from comparative PCI trials, and despite the
lack of dedicated studies, PCI in patients with MV-CAD
has become current practice.
Aim of the study. The EXECUTIVE (EXecutive RCT:
Evaluating XIENCE V in a Multi Vessel Disease) trial
(NCT00531011) aims to assess the efﬁcacy and perfor-
mance of the XIENCE V EES (Abbott Vascular, Santa
Clara, California) in the treatment of de novo coronary
artery lesions in patients with
MV-CAD (intended as 2- or
3-vessel disease). Its efﬁcacy in
preventing neointimal prolifera-
tion 9 months after stent place-
ment as assessed by quantitative
coronary angiography (QCA)was
also compared with the TAXUS
Libertè PES (Boston Scientiﬁc,
Natick, Massachusetts).
Methods
Detailed information regarding
the study protocol has been
published previously (17). In
brief, the EXECUTIVE trial is
a prospective, double-arm, ran-
domized multicenter trial com-
paring the XIENCE V EES to
the TAXUS Liberté PES in the
treatment of patients with MV-
CAD, performed in parallel to a nationwide, prospective,
open-label, single-arm registry evaluating the performance
of the EES in patients with 2- or 3-vessel MV-CAD treated
in daily practice. MV-CAD was deﬁned as in previous
recent studies of coronary revascularization by PCI or
coronary bypass surgery (1–4,6,7,18). The study wasUniversitaria Molinette San Giovanni Battista, Torino, Italy; and the yyyAbbott
Vascular Knoll-Ravizza S.p.A., Milano, Italy. This study was sponsored by Abbott
Vascular Knoll-Ravizza S.p.A., Italy. Dr. Ribichini has received a fee from
Abbott Vascular Knoll-Ravizza S.p.A. to design the study, develop the statistical
analysis, and write the manuscript. Dr. Bartorelli is on the advisory board of Abbott
Vascular. Drs. Lopera Quijada, Cappi, and Ribaldi are employees of Abbott Vascular
Knoll-Ravizza S.p.A. All other authors have reported that they have no relationships
relevant to the contents of this paper to disclose.
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1014conducted in 30 centers in Italy that enrolled 600 patients in
total.
The EXECUTIVE randomized trial enrolled 200
patients fulﬁlling the eligibility criteria. By randomization,
treatment was assigned in a 1:1 ratio to receive EES or PES.
In the EXECUTIVE registry, 400 patients with MV-CAD
suitable to receive treatment of coronary lesions with
multiple EES entered a prospective, controlled registry. The
study was approved by the medical ethics committee at each
participating center. All patients provided written informed
consent before their participation in this study. All patients
were screened for eligibility for recruitment according to the
Instructions For Use of the XIENCE V EES, and the
TAXUS Liberté PES.
The study ﬂowchart is shown in Figure 1, and the
inclusion/exclusion criteria are shown in Table 1.
Randomization and patient enrollment. After verifying the
selection (inclusion/exclusion) criteria, candidates were ran-
domized according to an automatic centralized allocation
system to 1 of 2 study arms. Selected sites recruited patients
with MV-CAD into either the randomized section or the
single-arm registry section (see the Online Appendix). No site
enrolled patients simultaneously in the randomized study and
the single-arm registry. The 2 study groups ran in parallel
from October 2008 to March 2010.
Revascularization technique and treatment strategy. The
most complete degree of revascularization was pursued,Figure 1. The CONSORT Diagram Showing Patients Study Flow
Study design and numbers of patients with follow up controls. EES ¼ ever-
olimus-eluting stent(s); PES ¼ paclitaxel-eluting stent(s).considering as equivalent both “anatomic,” which includes
all vessels with a signiﬁcant stenosis >70% irrespective of
viable myocardium, or “functional,” that is, only vessels with
signiﬁcant stenosis >70% supplying viable ischemic myo-
cardium (19). Because the completeness of the revasculari-
zation refers to the vessels suitable for PCI, small, tortuous,
or diffusely atheromatous vessels were not treated, but
all patients included in the study must have had at least
2 suitable major vessels treated with PCI and stent im-
plantation. All major epicardial coronary arteries could be
treated, with the exception of the left main trunk, and with
a planned maximum of 4 DES implanted. Staged proce-
dures to complete revascularization were allowed within
1 month of the index PCI.
The clinical risk of all patients entering the trial was
classiﬁed according to the EuroSCORE (20), and the an-
giographic complexity of the treated lesions was assessed by
the SYNTAX score obtained at baseline angiograms (21).
Stent implantation technique. Treatment of the target lesion
could be performed with either a single stent or planned
overlapping stents. Stents could be deployed either directly
or after pre-dilation. Post-dilation with noncompliant bal-
loons could be performed if appropriate. Bailout procedures
were performed in cases of major dissection; occlusive
complication; chest pain or ischemic electrocardiographic
changes that do not respond to repeat balloon inﬂations and
medical therapy. In the randomized study, the stent added in
bailout was of the same type of that designated by the
treatment allocation. In the single-arm registry, only EES
could be added.
Medication. Before PCI, all patients were pre-treated with
a loading dose of either ticlopidine 500 mg day for at least
48 h before, or clopidogrel 300 mg, ideally at least 6 h before
PCI, and conventional doses of aspirin (325 to 500 mg in
patients with acute coronary syndromes and 100 to 160 mg
in stable patients). During the procedure, patients received
intravenous heparin to maintain an activated clotting time
over 300 s. After successful stent implantation, all patients
received standard medications, including aspirin 100 to
160 mg/day, ticlopidine 250 mg twice daily, or clopidogrel
75 mg/day for at least 6 months. A regimen of dual anti-
platelet treatment was maintained for 12 months if well
tolerated in patients without augmented risk for bleeding.
Statins were recommended in all patients.
Patients participating in the randomized trial had planned
follow-up imaging and QCA at 9 months. Angiograms
were analyzed by an independent angiographic core labo-
ratory (Euro Imaging S.r.l., Rome, Italy) blinded to the
stent type.
EXECUTIVE randomized trial primary endpoint. The primary
endpoint of the randomized trial was in-stent lumen loss at
270-day follow-up. To avoid interlesion clustering of
restenosis, the protocol speciﬁed that a single lesion would
be randomly selected by computer for analysis of late loss.
Table 1. Inclusion/Exclusion Criteria
Inclusion Criteria Exclusion Criteria
General
1. Patient must be at least 18 years of age.
2. Written informed consent prior to any study-related procedure.
3. MVD, as documented by coronary angiography, i.e., presenting a severe
stenosis (>50%) amenable to PCI in at least 2 major epicardial vessels (15).
4. Patient must have evidence of myocardial ischemia (e.g., stable or unstable
angina, silent ischemia, positive functional study or a reversible change in the
ECG consistent with ischemia).
5. Patient must be an acceptable candidate for CABG surgery.
6. Patient must agree to undergo all protocol-required follow-up examinations.
1. Patient has had a known diagnosis of AMI within 72 h preceding the index
procedure (nonprocedural/spontaneous MI, CK-MB 2 times upper limit of
normal) and CK and CK-MB have not returned within normal limits at the time
of procedure.
2. Patient has a known LVEF <30%.
3. Patient is receiving chronic anticoagulation therapy.
4. Patient has a known hypersensitivity or contraindication to aspirin, paclitaxel,
either heparin or bivalirudin, clopidogrel or ticlopidine, everolimus, cobalt,
chromium, nickel, tungsten, acrylic and ﬂuoro polymers or contrast sensitivity
that cannot be adequately pre-medicated.
5. Elective surgery is planned within the ﬁrst 9 months (14 days) after the
procedure that will require discontinuing either aspirin or clopidogrel.
6. Patient has a platelet count <100,000 cells/mm3 or >700,000 cells/mm3,
a WBC of <3,000 cells/mm3, or documented or suspected liver disease
(including laboratory evidence of hepatitis).
7. Patient has known renal insufﬁciency (e.g., serum creatinine level of more than
2.5 mg/dl, patient on dialysis).
8. Patient has a history of bleeding diathesis or coagulopathy or will refuse blood
transfusions.
9. Patient has had a CVA or TIA within the past 6 months.
10. Patient has other medical illness (e.g., cancer or congestive heart failure) or
known history of substance abuse (alcohol, cocaine, heroin, etc.) that may
cause noncompliance with the protocol, confound the data interpretation, or
is associated with a limited life expectancy (i.e., <1 year).
11. Patient is already participating in another investigational-use device or drug
study or has completed the follow-up phase of another study within the last
30 days.
Angiographic
7. Patients may receive up to 4 planned XIENCE V EES stents, depending on the
number of vessels treated and their respective lesion length. When multiple
lesions are present in 1 or more main coronary branches, complete revascu-
larization should be attempted with the implantation of a maximum of
4 planned stents.
8. Target lesions must be de novo lesions (no prior stent implant, no prior
brachytherapy).
9. Target vessel reference diameter must be between 2.5 mm and 4.0 mm by
visual estimate.
10. Target lesion <28 mm by visual estimation.
12. Target lesion meets any of the following criteria:
 Left main location.
 Located within an arterial or saphenous vein graft or distal to a diseased
arterial or saphenous vein graft (deﬁned as vessel irregularity per angio-
gram and >20% stenosed lesion by visual estimation).
 Heavy calciﬁcation.
13. The patient may need more than 4 planned stents.
AMI ¼ acute myocardial infarction; CABG ¼ coronary artery bypass graft; CK ¼ creatine kinase; CK-MB ¼ creatine kinase–myocardial band; CVA ¼ cerebrovascular accident; ECG ¼ electrocardiogram;
EES ¼ everolimus-eluting stent; LVEF ¼ left ventricular ejection fraction; MI ¼ myocardial infarction; MVD ¼ minimal vessel diameter; PCI ¼ percutaneous coronary intervention; TIA ¼ transient ischemic
attack; WBC ¼ white blood cell count.
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1015All randomized lesions were instead included in the analysis
for other angiographic data.
EXECUTIVE randomized trial secondary endpoints. The
secondary endpoints are as follows:
 Stent thrombosis at 30 days and 1 year adjudicated as
per protocol and the Academic Research Consortium
deﬁnitions (22).
 Angiographic in-segment minimal lumen diameter
(MLD) and in-segment late loss at 270 days post-
procedure.
 Revascularizations: target lesion, target vessel (TVR),
or any revascularization at 30 days, and 1 year.
 Composite endpoint of cardiac death, myocardial
infarction, Q-wave and non–Q-wave, and ischemia-driven target lesion revascularization at 30 days and
1 year.
 Composite endpoint of all-cause death, myocardial
infarction (Q-wave and non–Q-wave), and TVR at
30 days and 1 year.
EXECUTIVE single-arm registry primary endpoint. The
primary endpoint is a composite endpoint of all-cause death,
myocardial infarction (Q-wave and non–Q-wave), and
ischemia-driven TVR at 1 year.
EXECUTIVE registry secondary endpoints. The secondary
endpoints of the registry are the same as the randomized
study, except for the angiographic assessment at 270 days.
Data management and statistical methods. Independent
study monitors veriﬁed all case report form data onsite. All
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1016major adverse cardiac events (MACE) were adjudicated by
an independent clinical events committee blinded to treat-
ment assignment with review of original source documen-
tation (see the Online Appendix).
Sample size calculation of the EXECUTIVE randomized trial.
The EXECUTIVE randomized trial aimed primarily to
demonstrate noninferiority of the XIENCE V with respect
to the TAXUS Libertè stent. If noninferiority was shown
and the in-stent late loss was found to be lower in the
XIENCE V arm, then superiority could be tested 2-sided
at the 5% level. The sample size for the randomized part of
the study was based on the primary endpoint of in-stent
late loss at 270 days and on the following assumptions: 1-
tailed noninferiority test; alpha ¼ 0.05; randomization
ratio 1:1; noninferiority margin delta 0.12; true mean in-
stent late loss and standard deviation are assumed to be
equal to 0.20  0.41 mm in the XIENCE V EES arm:
0.16  0.41 mm, 95% conﬁdence interval (CI): 0.11 to
0.20; and true mean in-stent late loss and standard devi-
ation are assumed to be equal to 0.30  0.53 mm in the
TAXUS Liberté stent arm. These assumptions are based
on SPIRIT III (A Clinical Evaluation of the Investiga-
tional Device XIENCE V Everolimus Eluting Coronary
Stent System [EECSS] in the Treatment of Subjects With
De Novo Native Coronary Artery Lesions) trial results at 8
months (14).
Given the aforementioned assumptions, analyzing 81
lesions per arm provides more than 90% power. In order to
account for dropouts and to ensure enough angiographic
data, 200 patients were enrolled (approximately 100 EES
and 100 PES). Sample size calculations were performed
using NCSS-PASS 2002 (NCSS, Version 15 Statistical
Software, Kaysville, Utah).
Sample size calculation of the executive registry. A sample
size of 500 patients (400 included in the registry and
100 treated with the EES in the randomized study)
produces a 2-sided 95% CI around clinical endpoint esti-
mates. Assuming from previous studies a true 1-year inci-
dence of the composite endpoint of all-cause death,
myocardial infarction (Q-wave and non–Q-wave), and
ischemia-driven TVR at 12 months rate comprised between
10% and 14%, the expected CIs, assuming 10% lost to
follow-up, were estimated to comprise between 7.4% and
17.6% (16). Half the width of the CI would vary between
2.9 and 3.4; 95% CIs have been calculated using Clopper-
Pearson.
Analysis population. The intention-to-treat population for
the EXECUTIVE randomized trial consisted of all patients
randomized to the study, regardless of the treatment actually
received.
Statistical analyses. The primary outcome had to be tested
using an analysis of covariance on 1 single randomized
lesion by patient: the model included the treatment effect
and post-procedure MLD value as quantitative covariate.Additionally, a supportive analysis was carried out by means
of a repeated measures analysis model, using recorded data
for all lesions and taking into account the interdependency
of lesions within patients, by using a mixed model method
with patient as random effect. Subgroup analysis was carried
out on primary outcome using separate mixed models,
including treatment, the subgroup factor and its interaction
with treatment, baseline (post-procedure MLD) as covari-
ate, and patient as random effect. A signiﬁcant treatment
by factor interaction indicates a signiﬁcantly different
treatment effect in 1 of the 2 categories. Patients and lesions
baseline and characteristics were checked for homogeneity
between XIENCE V and TAXUS Libertè groups using the
Student t test for continuous variables, the Fisher exact test
for binomial categorical variables, and the chi-square test for
multinomial qualitative ones. The same methods were used
to check homogeneity of characteristics between patients
included in the randomized trial and in the registry.Results
Between October 2008 and March 2010, 600 patients
were enrolled in 30 Italian sites. In the randomized study,
103 patients received 313 XIENCE V stents on 263 lesions,
and 97 patients received 314 TAXUS Liberté stents on
235 lesions. In the single-arm registry, 400 patients were
treated with 1,127 stents on 983 lesions (Fig. 1).
Baseline and procedural characteristics. Baseline character-
istics of the patients were well matched between the 2
randomized groups, and were not substantially different
from those of patients entered in the registry except for
a higher number of patients with elevated troponin in the
registry (Table 2). An additive EuroSCORE 6 was
calculated in 32% of the randomized patients (34% in the
EES arm, and 29.9% in the PES arm). The mean number of
lesions treated was 2.5  1.3 in each of the 3 groups. In
the PES arm of the randomized study, the baseline lesion
length was slightly longer (13.38  6.56 vs. 12.17  5.72,
p ¼ 0.03), there were some more bifurcation lesions (14.9%
vs. 9.1%, p ¼ 0.05), and distal dissections after stenting were
reported more frequently in this group, which may explain
the need for more stents per lesion (1.34  0.64 vs.
1.21  0.49, p ¼ 0.01) (23) (Table 3).
The angiographic characteristics at baseline of the 2 ran-
domized groups and a comparison between the patients en-
rolled in the registry and the randomized study are shown in
Table 3. The baseline angiographic complexity as assessed
by the SYNTAX score was low (12.7  5.24), whereas
the clinical risk was intermediate (mean logistic Euro-
SCORE¼ 4.79 5.6), and these were almost identical among
groups. A complete revascularization according to the PCI
strategy planned at enrollment was obtained in all randomized
cases and in 396 (99%) of the 400 patients entered in the
Table 2. Patients Baseline Characteristics
XIENCE RCT
(n ¼ 103)
TAXUS RCT
(n ¼ 97) p Value
All RCT
(n ¼ 200)
Registry
(n ¼ 400) p Value
Age, yrs 64.7  10 64.0  10 0.62 64.3  10.2 64.3  9.5 1.00
Male 76 (73.8) 69 (74.2) 0.75 149 (74.5) 317 (79.3) 0.21
Arterial hypertension 76 (73.8) 71 (76.3) 1.00 150 (75.0) 277 (69.3) 0.15
Current smokers 31 (30.1) 21 (22.6) 0.20 52 (26.0) 125 (31.3) 0.22
Dyslipidemia 72 (70.0) 63 (67.7) 0.55 137 (68.5) 242 (60.5) 0.06
Diabetes 24 (23.3) 30 (32.2) 0.27 55 (27.5) 136 (34) 0.11
Cerebrovascular disease 3 (2.9) 6 (6.5) 0.32 9 (4.5) 16 (4.0) 0.83
Previous myocardial infarction
NSTEMI >72 h 26 (25.2) 20 (21.5) 0.50 46 (23.0) 85 (21.3) 0.68
STEMI >72 h 20 (19.4) 16 (17.2) 0.71 36 (18.0) 70 (17.5) 0.91
Previous CABG 1 (1.0) 1 (1.0) 1.00 2 (1) 6 (1.5) 0.73
Previous PCI 15 (14.6) 19 (20.4) 0.35 34 (17.0) 74 (18.5) 0.74
LVEF, % 56.2  7.7 55.90  8.2 0.79 56.1  7.9 54.8  8.2 0.061
50 63 (61) 59 (61) 1.0 122 (61) 250 (62.5) 0.91
<50 >30 40 (39) 38 (39) 1.0 78 (39) 150 (37.5) 0.91
Unstable angina 41 (39.8) 40 (43.0) 0.89 81 (41) 171 (42.8) 0.66
Stable angina/silent ischemia 41 (39.8) 47 (50.5) 0.25 88 (44) 179 (44.8) 0.93
Positive TnI pre-PCI, %* 10 (9.1) 16 (15.8) 0.21 26 (13.0) 91 (22.8) 0.004
2-Vessel disease 72 (70) 57 (58.8) 0.11 129 (64.5) 282 (70.5) 0.14
3-Vessel disease 31 (30) 40 (41.2) 0.11 71 (35.5) 118 (29.5) 0.14
Syntax score, per patient 12.9  5.18 12.48  5.33 0.57 12.7  5.24 12.59  5.60 0.81
Syntax score, >22 6 (5.8) 5 (5.2) 1.00 11 (5.5) 22 (5.5) 1.00
EuroSCORE, logistic 4.3  3.8 5.3  6.9 0.22 4.79  5.57 4.36  5.35 0.36
EuroSCORE 6 23 (22.3) 22 (22.7) 1.00 45 (22.5) 70 (17.5) 0.15
Biochemical data
Total cholesterol, mg/dl 185.04  42.9 183.4  44.29 0.81 184.23  43.46 186.89  47.98 0.55
LDL cholesterol, mg/dl 110.8  34.44 108.81  37.45 0.74 109.77  35.92 115.3  42.36 0.18
HDL cholesterol, mg/dl 42.92  10.68 44.11  13.97 0.56 43.51  12.39 42.59  13.4 0.48
Triglycerides, mg/dl 150.23  81.27 151.87  72.07 0.89 151.04  76.66 145.38  78.53 0.45
Creatinine, mg/dl 0.95  0.23 1.02  0.3 0.07 0.98  0.26 0.99  0.26 0.72
Hemoglobin, g/dl 13.76  1.44 13.84  1.55 0.71 13.79  1.49 13.87  1.53 0.58
hs-CRP, mg/l 3.19  3.59 5.32  7.91 0.08 4.27  6.24 2.94  7.03 0.09
Data per treated lesions 263 235 498 983
Stents implanted, total 313 314 627 1127
Stents per patient 2.40  0.75 2.27  0.69 0.20 3.15  1.20 2.83  0.98 <0.001
Stents per lesion 1.21  0.49 1.34  0.64 0.012 1.27  0.56 1.16  0.42 <0.001
Stent length, mm 17.7  5.3 18.1  5.8 0.42 17.8  5.5 18.8  5.3 <0.001
Stent diameter, mm 2.88  0.41 3.03  1.81 0.22 2.95  1.29 2.93  0.66 0.75
Direct stenting 94 (35.9) 90 (38.1) 0.58 184 (36.9) 383 (39) 0.46
Values are mean  SD, n (%), or n. *Positive TnI levels are considered as >0.5 ng/l.
HDL ¼ high-density lipoprotein; hs-CRP ¼ high-sensitivity C-reactive protein; LDL ¼ low-density lipoprotein; NSTEMI; non–ST-segment elevation myocardial infarction; STEMI ¼ ST-segment elevation
myocardial infarction; RCT ¼ randomized controlled trial; TnI ¼ troponin I; other abbreviations as in Table 1.
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1017registry. There were no differences regarding balloon pressure
for stent deployment and direct stent implantation.
Follow-up. All patients entered in the study had 1-month
follow-up. In the randomized study, the pre-speciﬁed
angiographic follow-up at 9 months was obtained in 167
(84%) patients: 90 (87%) in the XIENCE V arm and 77
(79%) in the TAXUS Libertè arm. Clinical follow-up at
1 year was obtained in 99 and 91 patients in the XIENCE
V and TAXUS Libertè groups, respectively. Follow-up ofthe registry study at 1 year was obtained in 392 patients
(98%) (Fig. 1).
Angiographic outcomes. Table 4 shows the quantitative
angiographic measurements of all lesions of the randomized
arms and the results of the QCA at follow up observed in
all patients with an angiographic follow up (419 lesions).
Figure 2 shows in detail the late loss at 9 months of the
randomized study as a single lesion per patient analysis:
primary endpoint 90 XIENCE V and 77 TAXUS Libertè
Table 3. Baseline Characteristics and Procedural Details
XIENCE
(n ¼ 263)
TAXUS
(n ¼ 235) p Value*
All RCT
(n ¼ 498)
Registry
(n ¼ 983) p Value
ACC/AHA lesion classiﬁcationy
A 33 (12.5) 28 (11.9) 0.98 61 (12.2) 77 (7.8) <0.001
B1 82 (31.2) 77 (32.8) 159 (31.9) 471 (47.9)
B2 77 (29.3) 67 (28.5) 144 (28.9) 275 (28.0)
C 71 (27.0) 63 (26.8) 134 (26.9) 160 (16.3)
Type of lesion
Single 239 (90.9) 200 (85.1) 0.052 439 (88.2) 881 (89.6) 0.43
Bifurcation 24 (9.1) 35 (14.9) 59 (11.8) 102 (10.4)
Calciﬁcationy
Moderate 47 (17.9) 51 (21.7) 0.087 97 (19.5) 343 (34.9) <0.001
Severe 2 (0.8) 7 (2.9) 8 (1.6) 21 (2.1)
Thrombusy
Moderate 19 (7.2) 18 (7.7) 0.60 37 (7.4) 49 (5.0) 0.017
Severe 5 (1.9) 2 (0.9) 7 (1.4) 4 (0.4)
Diffuse 64 (24.3) 68 (28.9) 0.26 132 (26.5) 257 (26.1) 0.90
Ostial 14 (5.3) 14 (6.0) 0.85 28 (5.6) 54 (5.5) 0.90
TIMI ﬂow pre-PCI
3 206 (78.3) 200 (85.1) 0.059 406 (81.5) 808 (82.2) 0.96
2 41 (15.6) 21 (8.9) 62 (12.4) 122 (12.4)
1 7 (2.7) 10 (4.3) 17 (3.4) 31 (3.1)
0 9 (3.4) 4 (1.7) 13 (2.6) 22 (2.2)
Vessel treated
LAD 108 (41.1) 104 (44.3) 0.74 212 (42.6) 394 (40) 0.24
Circumﬂex 83 (31.6) 68 (28.9) 151 (30.3) 281 (28.6)
RCA 72 (27.4) 63 (26.8) 135 (27.1) 308 (31.3)
Noncompliant BD 79 (30.0) 81 (34.5) 0.29 160 (32.1) 411 (41.8) <0.001
Reference vessel
Diameter 2.60  0.59 2.62  0.61 0.71 2.61  0.60 2.61  0.64 1.00
Diameter stenosis 72.15  13.88 71.59  11.93 0.63 71.88  12.98 70.22  11.54 0.014
Lesion length 12.17  5.72 13.38  6.56 0.030 16.31  6.73 15.52  5.76 0.019
Values are n (%) or mean  SD. *Student t test for continuous variables, Fisher exact test for type of lesion, diffuse, ostial, culprit, complete
revascularization, and noncompliant BD post-dilation, and chi-square test for other qualitative ones. yAs deﬁned by American College of Cardiology
(ACC)/American Heart Association (AHA) (23).
BD ¼ balloon dilation; LAD ¼ left anterior descending coronary artery; NC ¼ noncompliant balloon; RCA ¼ right coronary artery;
TIMI ¼ Thrombolysis In Myocardial Infarction; other abbreviations as in Tables 1 and 2.
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1018(Fig. 2A) and 225 XIENCE V and 194 TAXUS Libertè all
lesions analysis (Fig. 2B). The primary endpoint of in-stent
late loss in the analysis per single lesion was signiﬁcantly
less in the EES group compared with the PES group (0.03
 0.49 mm vs. 0.23  0.51 mm, p ¼ 0.001). Similar results
were observed in the analysis of all lesions (0.05  0.51 mm
vs. 0.24  0.50 mm, p < 0.001).
Clinical outcomes. At 30 days, the incidence of clinical
events was similar in the 2 randomized groups (1.0% and
2.2% in the EES and PES groups, respectively), and
slightly higher in the registry (4.7%) (Table 5). At 1 year,
74% and 67% of patients were still under dual antiplatelet
therapy in the EES and PES randomized groups, respec-
tively, 20% and 28% were on aspirin alone, and 6% and 5%
had stopped both drugs (p ¼ 0.3). In the registry, 70%
were still on dual antiplatelet therapy, 26% on aspirin, and4% had stopped both drugs. In the XIENCE V group, 1
patient died 3 days after the procedure because of heart
failure, and 1 patient died in the TAXUS Libertè group at
1 year likely because of a possible stent thrombosis. For the
analysis of the clinical performance in the registry study,
the 400 patients included in the registry were pooled with
the 103 enrolled in the XIENCE V arm of the randomized
study, for a total of 503 patients, 491 of whom had 1-year
follow-up. The occurrence of clinical events was similar
between patients entered in the registry and those included
in the randomized study. Of note, most of the events
classiﬁed as myocardial infarctions occurred within 1
month and were periprocedural, whereas very few cases
occurred spontaneously during follow-up. The clinical
outcome of the whole study population is detailed in
Table 5.
Table 4. Angiographic Quantitative Assessment (Descriptive Statistics
for All Lesions)
XIENCE
(n ¼ 263)
TAXUS
(n ¼ 235) p Value
Pre-procedural QCA
D-Ref, mm 2.59  0.57 2.66  0.62 0.24
MLD, mm 0.74  0.43 0.75  0.38 0.88
Stenosis, % 71.97  14.11 71.90  12.09 0.95
Post-procedural, QCA
D-Ref, mm 2.72  0.47 2.77  0.46 0.24
In-stent MLD, mm 2.34  0.48 2.412  0.47 0.15
In-segment MLD, mm 2.00  0.49 2.08  0.48 0.10
In-stent stenosis, % 13.97  9.36 13.28  8.49 0.43
In-segment stenosis, % 26.77  11.35 25.39  10.78 0.20
Acute gain, mm 1.60  0.56 1.66  0.44 0.22
9-Month angiographic follow-up 225 lesions 194 lesions
D-Ref, mm 2.86  0.54 2.74  0.54 0.042
In-stent MLD, mm 2.29  0.64 2.17  0.61 0.055
In-segment MLD, mm 2.1  0.57 2.042  0.52 0.28
In-stent stenosis, % 20.15  14.99 21.66  15.78 0.31
In-segment stenosis, % 26.87  12.59 22.3  60 0.27
In-stent LL, mm 0.05  0.51 0.24  0.50 <0.001
In-segment LL, mm 0.10  0.48 0.037  0.42 0.002
Values are mean  SD or n.
D-ref ¼ reference diameter; LL ¼ late loss; MLD ¼ minimum lumen diameter;
QCA ¼ quantitative coronary analysis.
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Figure 2. Primary Endpoint
(A) Late lumen loss at 9 months from 1 lesion per patient. (B) Late lumen loss
at 9 months from all lesions treated.
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1019Subgroup analysis for the randomized study. The results
for the primary endpoint in subgroups of patients according
to diabetic status, lesion length, multiple stenting, SYNTAX
score, EuroSCORE, and the degree of vessel disease are
shown in Figure 3. The analysis shows an overall signiﬁcant
superiority of the EES (p ¼ 0.0026) and a consistent trend
in favor of the EES in all subgroups. Signiﬁcantly better
angiographic outcomes with EES were observed in patients
treated with a single stent per lesion (p ¼ 0.001), patients
with shorter lesions (p ¼ 0.001), nondiabetic patients
(p ¼ 0.039), patients with 2-vessel disease (p ¼ 0.019), and
in patients with a higher EuroSCORE (p ¼ 0.003).Discussion
Although implantation of DES in patients with MVD has
become common practice, data about efﬁcacy and safety of
DES in this speciﬁc setting are scarce. Indeed, most of the
available data derive from the analysis of subgroups of
patients treated with multiple stenting in trials that allowed
the inclusion of patients with maximum 2-vessel disease or
with nonspeciﬁed MV-CAD (24,25), whereas in most of
the seminal DES studies, this characteristic was a pre-
speciﬁed exclusion criterion (26–30). Therefore, the study of
the efﬁcacy and safety of new-generation DES in this
context deserves further study.Our trial shows the angiographic superiority of EES over
PES in the speciﬁc setting of patients with 2- and 3-vessel
disease. Indeed, the late luminal loss observed in this study is
very low, even lower than that reported in previous studies
that assessed the same stents with a lower number of
observations. This is true in all the treated lesions (0.05 
0.51 mm vs. 0.24  0.50 mm, p < 0.001), as well as in the
pre-speciﬁed analysis of 1 lesion per patient (0.03  0.49
mm vs. 0.23  0.51 mm, p ¼ 0.001).
From a clinical standpoint, the results observed at 1 year
in the 503 patients treated with EES in the EXECUTIVE
trial yielded a very low rate of MACE, with a composite of
death, myocardial infarction, and ischemia-driven TVR of
9.2%, a reassuring ﬁnding considering that most myocar-
dial infarctions were peri-procedural and not spontaneous
during follow-up. Such results closely replicate the ob-
servations derived from lower-risk populations of MV
patients such as those analyzed in the SPIRIT III and
IV (Clinical Evaluation of the XIENCE V Everolimus
Eluting Coronary Stent System in the Treatment of
Table 5. Clinical Results
XIENCE
(n ¼ 103)
TAXUS
(n ¼ 97)
All RCT
(n ¼ 200)
Registry All
(n ¼ 503)
0–1 Month
Cardiac death 1 (1.0) d 1 (0.5) 2 (0.4)
Noncardiac death d d d d
Target vessel QMI d d d 3 (0.6)
Target vessel NQMI d 2 (2.2) 2 (1.1) 17 (3.5)
TLR–TVR–non-TVR d d d 1 (0.2)
Subacute stent thrombosis d d d 1 (0.2)
All MACE (all-cause death, MI, and TVR) 1 (1.0) 2 (2.2) 3 (1.6) 23 (4.7)
0–12 Months 99 91 190 491
Cardiac death 1 (1.0) 1 (1.1) 2 (1.1) 2 (0.4)
Noncardiac death d d d 1 (0.2)
Target vessel QWMI d d d 3 (0.6)
Target vessel NQWMI 1 (1.0) 3 (3.3) 4 (2.1) 20 (4.1)
ID-TLR 6 (6.1) 7 (7.7) 13 (6.8) 16 (3.3)
NID-TLR 1 (1.0) 2 (2.2) 3 (1.6) 2 (0.4)
ID-TVR 2 (2.0) 2 (2.2) 4 (2.1) 4 (0.8)
NID-TVR 1 (1.0) 3 (3.3) 4 (2.1) 1 (0.2)
No TVR revascularization 5 (5.1) 1 (1.1) 6 (3.2) 8 (1.6)
Deﬁnite stent thrombosis (ARC) d d d d
Probable stent thrombosis (ARC) d d d 1 (0.2)
Possible stent thrombosis (ARC) d 1 (1.1) 1 (0.5) d
All MACE (all-cause death, MI, and TVR) 11/99 (11.1)* 15/91 (16.5)* 26/190 (13.7) 45/491 (9.2)
Values are % n, n, or n/N (%). *p value: Fisher exact test to compare XIENCE and TAXUS; p ¼ 0.30.
ARC ¼ Academic Research Consortium; ID ¼ ischemia-driven; MACE ¼ major adverse clinical event; MI ¼ myocardial infarction; NID ¼ non-
ischemia driven; NQMI ¼ non–Q-wave myocardial infarction; QMI ¼ Q-wave myocardial infarction; RCT ¼ randomized controlled trial; TLR ¼ target
lesion revascularization; TVR ¼ target vessel revascularization.
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studies (6.2%), as well as in the most recent Resolute All-
Comers study that showed a 9.7% of all MACE at 1 year
in the EES-treated arm (31,32).
The EES XIENCE V is a second-generation DES in
which the drug is released from a thin (7.8 mm) nonadhesive,
durable, biocompatible ﬂuorinated copolymer onto a
low-proﬁle (0.0813-mm) strut thickness, ﬂexible cobalt–
chromium stent. Everolimus is an effective antiproliferative
agent through the inhibition of growth factor–stimulated
cell proliferation by causing cell cycle arrest in the late G1
stage in the cell cycle. Pre-clinical studies have shown more
rapid and more complete endothelialization with this stent
compared with sirolimus-eluting and paclitaxel-eluting
stents (33), and clinical studies with the EES have
demonstrated its superiority over the PES TAXUS Express
(14–16).
The SPIRIT III randomized study enrolled 1,002 patients
with mainly single coronary disease. Angiographic follow-up
was planned for a subset of 564 patients at 240 days and
showed that the EESwas superior to the PES (in-segment late
loss 0.14  0.4 mm vs. 0.28 0.48 mm, p < 0.004). More-
over, at 2-year follow-up, treatment with EES compared with
PES resulted in a signiﬁcant 32% reduction in target vesselfailure (10.7% vs. 15.4%; hazard ratio, 0.68; 95% CI: 0.48 to
0.98; p ¼ 0.04) and a 45% reduction in MACE (7.3% vs.
12.8%; hazard ratio, 0.55; 95% CI: 0.36 to 0.83; p ¼ 0.004)
(14).
EXECUTIVE represents a unique population with MV-
CAD patients treated with DES at an intermediate clinical
risk (additive EuroSCORE 6 in 32% of the randomized
patients), and with low angiographic complexity (SYNTAX
score 22 in 95% of patients, mean 12.7  5.24). The
calculation of risk, taking into account both the angiographic
severity of CAD and the clinical risk, has been proposed as
a “global risk score,” a new classiﬁcation that may better
deﬁne the subgroups of patients with MV-CAD requiring
myocardial revascularization (34). Patients enrolled in the
EXECUTIVE trial represent a less complex cohort under an
angiographic standpoint compared with the population
assessed in the SYNTAX (28.4  11.5) and the ARTS II
(Arterial Revascularization Therapies Study II) studies (20.8
 9.5), with a logistic EuroSCORE 4.79  5.6, compared
with 3.8  2.6 in the SYNTAX trial, and 2.12  15.2 in
the ARTS II trial (7,8).
Study limitations. The trial was not powered to test clinical
differences. Furthermore, due to some protocol restrictions,
few patients in the EXECUTIVE trial had intermediate
Figure 3. Landmark Analysis of the Primary Endpoint in Different Subgroups
The p value is from the test statistic for testing the interaction between the treatment and any subgroup variable. Cl ¼ conﬁdence interval.
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1021SYNTAX scores; none was in the highest range >32, and
none had left ventricular ejection fraction <30%. These
exclusion criteria were introduced to allow patients with
severe and diffuse forms of CAD the possibility of surgical
revascularization, a treatment that was shown to offer better
clinical results and that had proved more appropriate in
patients with high angiographic complexity, as recom-
mended in the most recent international documents
(10–12). For the same reason, the criteria used in the
SYNTAX trial to evaluate the completeness of revasculari-
zation could not be applied. Due to the limited sample size,
some minor angiographic and procedural baseline charac-
teristics were observed. For the same reason, the statistical
analysis of subgroups yields nonsigniﬁcant results among
subgroups with the lower number of observations.Conclusions
The results obtained in EXECUTIVE trial show that
patients with 2- and 3-vessel disease having low-to-inter-
mediate SYNTAX scores, with intermediate clinical risk,
and belonging to a low-to-intermediate “global risk score”
classiﬁcation, have signiﬁcantly better angiographic results of
multiple PCI with the use of EES rather than with PES.
These data, supported by the low incidence of clinical
events, may help to further improve the currently known
outcomes of PCI in patients with MVD. The ongoing
EXCEL study (Evaluation of XIENCE PRIME or
XIENCE V versus Coronary Artery Bypass Surgery for
Effectiveness of Left Main Revascularization) willinvestigate the performance of EES XIENCE V compared
with coronary surgery in patients with left main stenosis
eventually associated with MV-CAD, and will provide
additional knowledge about myocardial revascularization
strategies in patients with MV-CAD.
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